Present challenges impacting the management of psychological symptoms in patients receiving CAR-T therapy or stem cell transplantation.

IF 1.5 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-10-08 DOI:10.1080/14737167.2025.2572317

Amber Feng, Madhuri Gottam, Wil L Santivasi, Thomas W LeBlanc

{"title":"Present challenges impacting the management of psychological symptoms in patients receiving CAR-T therapy or stem cell transplantation.","authors":"Amber Feng, Madhuri Gottam, Wil L Santivasi, Thomas W LeBlanc","doi":"10.1080/14737167.2025.2572317","DOIUrl":null,"url":null,"abstract":"Introduction: Hematopoietic stem cell (HSCT) and chimeric antigen receptor T-cell (CAR-T) therapy are crucial in the treatment of hematologic malignancies. While HSCT has been long established as a mainstay of the treatment of these diseases, CAR-T is a newer therapy with the potential to change the treatment landscape. Both cellular therapies are time and resource intensive, which has put stressors on patients that are unique from those associated with other forms of oncologic treatment.Areas covered: In this review, we discuss the current state of knowledge of psychological symptoms associated with HSCT and CAR-T and their management. In addition, we discuss the models of patient reported outcomes (PROs) used to perform this research. We performed a literature review on PubMed using keywords including 'palliative care, palliative care integration, hematologic malignancy, patient reported outcome, psychological care, and quality of life.' We included papers published before 1 April 2025.Expert opinion: We propose further investigations into integrated models of oncologic and palliative care teams and their efficacy.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":1.5000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2572317","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Hematopoietic stem cell (HSCT) and chimeric antigen receptor T-cell (CAR-T) therapy are crucial in the treatment of hematologic malignancies. While HSCT has been long established as a mainstay of the treatment of these diseases, CAR-T is a newer therapy with the potential to change the treatment landscape. Both cellular therapies are time and resource intensive, which has put stressors on patients that are unique from those associated with other forms of oncologic treatment.

Areas covered: In this review, we discuss the current state of knowledge of psychological symptoms associated with HSCT and CAR-T and their management. In addition, we discuss the models of patient reported outcomes (PROs) used to perform this research. We performed a literature review on PubMed using keywords including 'palliative care, palliative care integration, hematologic malignancy, patient reported outcome, psychological care, and quality of life.' We included papers published before 1 April 2025.

Expert opinion: We propose further investigations into integrated models of oncologic and palliative care teams and their efficacy.

查看原文本刊更多论文

目前的挑战影响心理症状管理的患者接受CAR-T治疗或干细胞移植。

造血干细胞（HSCT）和嵌合抗原受体t细胞（CAR-T）治疗在血液系统恶性肿瘤的治疗中至关重要。虽然造血干细胞移植长期以来一直是治疗这些疾病的主要方法，但CAR-T是一种较新的治疗方法，有可能改变治疗前景。这两种细胞疗法都是时间和资源密集型的，这给患者带来了与其他形式的肿瘤治疗相关的独特压力。涵盖领域：在这篇综述中，我们讨论了与造血干细胞移植和CAR-T相关的心理症状及其处理的现状。此外，我们讨论了用于执行本研究的患者报告结果（PROs）模型。我们在PubMed上进行了文献综述，关键词包括“姑息治疗、姑息治疗整合、血液恶性肿瘤、患者报告的结果、心理治疗和生活质量”。我们纳入了2025年4月1日之前发表的论文。专家意见：我们建议进一步研究肿瘤和姑息治疗团队的整合模式及其疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.